{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:18:26Z","timestamp":1791119906974,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>The use of statins has increased exponentially over the last 2 decades. Consequently, side effects have also increased, with muscle-related side effects commonly reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Although once thought to be only associated with self-limited direct myotoxicity, statins have recently been described in association with an autoimmune myopathy in association with antibodies directed against 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate limiting enzyme in cholesterol synthesis and the pharmacologic target of statins. Since this discovery, various cohorts have been identified worldwide and highlight both similarities and differences among them.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Recent studies from different fields have revealed diverse aspects of anti-HMGCR-associated immune-mediated necrotizing myopathy (IMNM). HMGCR IMNM is a unique autoimmune disease characterized by a well defined environmental trigger (statins) and a strong association with a genetic risk factor (Human leukocyte antigen D related B 1<jats:sup>\u2217<\/jats:sup>11\u200a:\u200a01). New diagnostic modalities have been established to confirm the presence of anti-HMGCR antibody and confirm the diagnosis of HMGCR IMNM. Clinical studies have shown that disease severity, as measured by muscle strength, as well as the rate of response to treatment have been associated with age at disease onset. Furthermore, a case series supported that intravenous immunoglobulin administration, perhaps even as monotherapy, may be a beneficial therapeutic intervention for selected patients.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000438","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T23:55:18Z","timestamp":1504050918000},"page":"604-611","source":"Crossref","is-referenced-by-count":31,"title":["Immune-mediated necrotizing myopathy associated with statins: history and recent developments"],"prefix":"10.1097","volume":"29","author":[{"given":"Eleni","family":"Tiniakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0889-857X(02)00032-7","article-title":"Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies","volume":"28","author":"Targoff","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium","volume":"29","author":"Endo","year":"1976","journal-title":"J Antibiot (Tokyo)"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2015.12.015","article-title":"Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey","volume":"245","author":"Hovingh","year":"2016","journal-title":"Atherosclerosis"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10557-017-6727-0","article-title":"Identification and management of statin-associated symptoms in clinical practice: extension of a clinician survey to 12 further countries","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.22205","article-title":"Prevalence and risk factors of muscle complications secondary to statins","volume":"44","author":"El-Salem","year":"2011","journal-title":"Muscle Nerve"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","article-title":"Muscle-related side-effects of statins: from mechanisms to evidence-based solutions","volume":"26","author":"Taylor","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bcp.12360","article-title":"Mechanisms and assessment of statin-related muscular adverse effects","volume":"78","author":"Mosshammer","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.revmed.2003.10.013","article-title":"Polymyositis induced or associated with lipid-lowering drugs: five cases","volume":"25","author":"Fauchais","year":"2004","journal-title":"Rev Med Interne"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.bor.0000245730.25383.97","article-title":"Statin myopathy: an update","volume":"18","author":"Christopher-Stine","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.25127","article-title":"Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy","volume":"54","author":"Floyd","year":"2016","journal-title":"Muscle Nerve"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1212\/NXI.0000000000000172","article-title":"Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease","volume":"2","author":"Mammen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R24-20230829","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2016.09.005","article-title":"Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories","volume":"15","author":"Alvarado-Cardenas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of antisignal recognition protein and anti3-hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS One"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/kev229","article-title":"Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience","volume":"54","author":"Klein","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/imj.13023","article-title":"HMGCR-associated myositis: a New Zealand case series and estimate of incidence","volume":"46","author":"Kennedy","year":"2016","journal-title":"Intern Med J"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1097\/MD.0000000000000416","article-title":"Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan","volume":"94","author":"Watanabe","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multicenter study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies are associated with DRB1\u221707:01 and severe myositis in pediatric myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","article-title":"Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies","volume":"56","author":"Liang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in Juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1\u221711:01 in antihydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0000000000003160","article-title":"HLA-DRB1 alleles in immune-mediated necrotizing myopathy","volume":"87","author":"Ohnuki","year":"2016","journal-title":"Neurology"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-induced anti-HMGCR-associated myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: a comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201711000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T15:18:48Z","timestamp":1719415128000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201711000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000438","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}